Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CTH | P32929 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21648134 | 0.90 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBMEN1KMT2A | |
| SCHEMBL20298597 | 0.88 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1KMT2ACYP2C19L3MBTL1 | |
| SCHEMBL21648073 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAPOLBCTHMEN1 | |
| SCHEMBL21648133 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAMEN1KMT2ACYP2C19 | |
| SCHEMBL12108477 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAPOLBCTHMEN1 | |
| SCHEMBL20298591 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAKMT2AALDH1A1USP2 | |
| SCHEMBL21648065 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAPOLBCTHMEN1 | |
| SCHEMBL21648207 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAPOLBCTHMEN1 | |
| SCHEMBL21648128 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAPOLBCTHMEN1 | |
| SCHEMBL21648125 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAPOLBCTHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030215-A1 | AQUEOUS COMPOSITION COMPRISING A COMPOUND OF THIOLACTONE TYPE AND A SILICONE AND PROCESS FOR TREATING KERATIN MATERIALS WITH THE COMPOSITION | L'OREAL (FR) | 2020-01-30 | — | — | US | disclosed |
| US-20200031796-A1 | COMPOSITION COMPRISING A COMPOUND OF THIOLACTONE TYPE AND A PARTICULAR SOLVENT AND PROCESS FOR TREATING KERATIN MATERIALS WITH THE COMPOSITION | L'OREAL (FR) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030215-A1 | AQUEOUS COMPOSITION COMPRISING A COMPOUND OF THIOLACTONE TYPE AND A SILICONE AND PROCESS FOR TREATING KERATIN MATERIALS WITH THE COMPOSITION | KRT18, MUC1, MGMT | SMN1; SMN2 3610/4885LMNA 760/4885POLB 1928/4885 |
| US-20200031796-A1 | COMPOSITION COMPRISING A COMPOUND OF THIOLACTONE TYPE AND A PARTICULAR SOLVENT AND PROCESS FOR TREATING KERATIN MATERIALS WITH THE COMPOSITION | KRT18, KRTCAP2, MUC1 | SMN1; SMN2 4724/4885LMNA 1504/4885POLB 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.